title: A randomized study comparing the efficacy of bevacizumab and ranibizumab as pre-treatment for pars plana vitrectomy in proliferative diabetic retinopathy.
abstract: OBJECTIVE
  To compare intravitreal bevacizumab versus ranibizumab as adjuvant treatment prior to pars plana vitrectomy (PPV) in proliferative diabetic retinopathy (PDR) with respect to parameters of surgical complexity.
  
  
  METHODS
  Prospective, randomized, double-masked pilot study of patients requiring PPV for nonclearing vitreous hemorrhage or tractional retinal detachment (TRD) secondary to PDR. Patients were randomized to receive either intravitreal bevacizumab or ranibizumab at standard doses 1 week preoperatively. Measured parameters included total surgical time, presence of TRD, intraoperative bleeding, iatrogenic retinal breaks, and use of endolaser and endodiathermy or silicone oil.
  
  
  RESULTS
  A total of 29 patients were recruited. For surgical parameters, there were no statistically significant differences between the groups in the univariate analyses. Multivariable analysis showed no statistically significant difference for total surgical time.
  
  
  CONCLUSIONS
  This pilot study suggests that intravitreal bevacizumab and ranibizumab are equivalent as surgical adjuvants when used as pre-treatment in patients with PDR undergoing PPV.
authors.forename: Kaivon
authors.initials: K
authors.lastname: Pakzad-Vaezi
authors.forename: David A
authors.initials: DA
authors.lastname: Albiani
authors.forename: Andrew W
authors.initials: AW
authors.lastname: Kirker
authors.forename: Andrew B
authors.initials: AB
authors.lastname: Merkur
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Kertes
authors.forename: Kenneth T
authors.initials: KT
authors.lastname: Eng
authors.forename: Nader
authors.initials: N
authors.lastname: Fallah
authors.forename: Farzin
authors.initials: F
authors.lastname: Forooghian
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D000069579:Ranibizumab; D012163:Retinal Detachment / Q000188:drug therapy / Q000601:surgery / Q000628:therapy; D013810:Therapeutic Equivalency; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014821:Vitrectomy; D014823:Vitreous Hemorrhage / Q000188:drug therapy / Q000601:surgery / Q000628:therapy
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006442:Glycated Hemoglobin; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A; C467484:VEGFA protein, human; C517652:hemoglobin A1c protein, human